间歇性恩杂鲁胺治疗复发性前列腺癌:睾酮动力学与相关毒性
本研究纳入38例生化复发前列腺癌患者,给予间歇性恩杂鲁胺单药治疗3个月(无雄激素剥夺),前瞻性监测血清睾酮与不良事件。结果显示睾酮中位峰值832.5 ng/dL(中位升高63%),16例(42%)报告男性乳房发育症状,但乳房发育与睾酮峰值水平或升高持续时间均无相关性。
要点
- 恩杂鲁胺单药治疗可致睾酮中位升高63%,峰值达832.5 ng/dL。
- 42%患者报告男性乳房发育症状,但与睾酮峰值或升高持续时间无关。
- 第一疗程出现乳房发育不能完全预测第二疗程的发生率。
核心结论
- ARPI单药治疗相关的睾酮升高与男性乳房发育发生率之间无直接相关性。
研究设计与样本
- 本分析评估生化复发前列腺癌患者接受间歇性恩杂鲁胺单药治疗(每疗程3个月,无雄激素剥夺)期间血清睾酮变化及男性乳房发育发生率,共纳入38例患者。
主要发现
- 患者中位年龄64.6岁,中位(范围)血清PSA为4.38(2.01-19.43)ng/mL,中位(范围)血清睾酮为316(167-723)ng/dL。
- 睾酮中位峰值832.5 ng/dL,中位升高63%。
- 16例(42%)患者报告男性乳房发育症状。
- 男性乳房发育与睾酮峰值水平或睾酮升高持续时间均无相关性。
- 第一疗程出现男性乳房发育不能完全预测第二疗程的发生率。
临床怎么用
- 恩杂鲁胺单药治疗期间应前瞻性监测睾酮与男性乳房发育症状,但不应仅依据睾酮峰值预测乳房发育风险。
局限性
- 样本量较小(38例),需进一步研究以优化ARPI单药治疗的临床实践。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To determine the relationship between gynaecomastia and testosterone levels in patients with biochemically recurrent prostate cancer treated with androgen receptor pathway inhibitor (ARPI) monotherapy. PATIENTS AND METHODS: This analysis evaluates changes in serum testosterone and the incidence of gynaecomastia. Patients with biochemically recurrent prostate cancer were given 3 months of enzalutamide intermittently with no androgen deprivation. Serum testosterone was within the normal range. Testosterone and adverse events were monitored prospectively. RESULTS: A total of 38 patients were enrolled with a median age of 64.6 years, median (range) serum prostate-specific antigen level of 4.38 (2.01-19.43) ng/mL, and median (range) serum testosterone level of 316 (167-723) ng/dL. Testosterone had a median peak of 832.5 ng/dL (median increase of 63%). Gynaecomastia symptoms were reported in 16 (42%) patients. There was no correlation with either peak testosterone level or duration of elevated testosterone and gynaecomastia. Patients with gynaecomastia with Course 1 of therapy did not fully predict the incidence of gynaecomastia for Course 2. CONCLUSIONS: In this study, there is no direct correlation between ARPI monotherapy-associated testosterone elevation and the incidence of gynaecomastia. The interactions of ARPI monotherapy, gynaecomastia, and testosterone elevation are more nuanced than previously thought and require further study to optimise ARPI monotherapy in clinical practice.
引用
- Marte JL, Hankin A, Williams M, et al. Intermittent enzalutamide in recurrent prostate cancer: testosterone kinetics and related toxicity. BJU Int. 2026. PMID: 42733186. doi:10.1111/bju.70443
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。